Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Hepatocellular Carcinoma: early-phase trial registry
65 of 146 indexed Hepatocellular Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #80 of 28,707 conditions by registered trial count.
146 US clinical trials · 65 currently recruiting · #80 of 28,707 conditions by registered trial count
Hepatocellular Carcinoma: 146 US clinical trials tracked, 65 recruiting.
Hepatocellular Carcinoma is the subject of 146 registered US clinical trials on ClinicalTrials.gov, 65 of them currently open to new participants. 20 are in Phase 3-4 (later-stage) and 92 in Phase 1-2 (earlier-stage). The most active sponsor is AstraZeneca, running 8 of these trials.
Enrollment posture brief
Registry condition hepatocellular-carcinoma
OPEN 65 | RECR 45% | LATE 20 | EARLY 92 | RANK #80 | SPON 8
Volume-matched condition peers
Nearest open-share peer: Critical Illness (45% recruiting · 92 trials)
Hepatocellular Carcinoma lists 65 open slots (45% of 146 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Hepatocellular Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Hepatocellular Carcinoma is recruiting above its size-band peers.
65 of 146 indexed trials (44.5%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Hepatocellular Carcinoma trials is spread across many organizations.
AstraZeneca accounts for 8 of 146 trials (5.5%). 94 distinct sponsors appear on at least one study for this condition label.
-
Typical Hepatocellular Carcinoma enrolment sits around 70 participants.
Median target enrolment is 70 among the 146 trials that report a genuine target (sentinel values excluded). 82 of those (56.2%) plan for fewer than 100 participants.
-
Hepatocellular Carcinoma research is mostly interventional.
129 interventional and 17 observational studies make up this index (88.4% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
146 total, page 1 of 3
A Multicenter Cancer Biospecimen Collection Study
Cofactor Genomics
NCT04510129
Molecular Basis of Pediatric Liver Cancer
University of Pittsburgh
NCT03959800
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
AstraZeneca
NCT06921785
Multi-analyte Blood Test Clinical Trial
Helio Genomics
NCT05199259
Multilevel Determinants of Socioeconomic Disparities in Geographic Late-Stage Hepatocellular Carcinoma Hotspots
University of Southern California
NCT07312162
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT05208762
A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
AbbVie
NCT06109272
CEUS vs. AMRI for HCC Detection in Patients With Indeterminate Liver Nodules
University of Texas Southwestern Medical Center
NCT06184152
National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer
National Cancer Institute (NCI)
NCT04145141
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
Mohamed Abdel-Rahman
NCT04792463
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
Diwakar Davar
NCT07223424
Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
Can-Fite BioPharma
NCT05201404
An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer
City of Hope Medical Center
NCT06342414
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
National Cancer Institute (NCI)
NCT06503146
First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours
AstraZeneca
NCT06795022
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
AstraZeneca
NCT05775159
Liver Cancer Disparities in American Indian and Alaska Native Persons
University of Washington
NCT05304234
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
Tvardi Therapeutics, Incorporated
NCT05440708
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma
NCT06362369
Adjuvant IP-001 Treatment for HCC Patients Following Surgical Resection and Ablation or Ablation Alone
Robert C. Martin
NCT06526338
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
Anwaar Saeed
NCT03539822
Targeted Navigation in Hepatocellular Carcinoma (HCC)
University of Miami
NCT06260943
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Nammi Therapeutics
NCT06582017
A Study of ZW251 in Participants With Advanced Solid Tumors
Zymeworks BC
NCT07164313
Impact of "Teaching the Teachers" Concept on Global Education and Application of Hepatocellular Carcinoma Diagnosis Guidelines
M.D. Anderson Cancer Center
NCT05143619
An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
Virogin Biotech Canada
NCT05223816
IDOV-Immune for Advanced Solid Tumors
ViroMissile
NCT06910657
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
Dan Zandberg
NCT04114136
A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma
Coherus Oncology
NCT06679985
Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer
Massachusetts General Hospital
NCT03482102
A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer
TORL Biotherapeutics
NCT06005740
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
St. Jude Children's Research Hospital
NCT05468359
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
BioEclipse Therapeutics
NCT04282044
A Trial Utilizing 18F-FS PG PET to Guide Therapy in Hepatocellular Carcinoma
M.D. Anderson Cancer Center
NCT07116486
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Replimune
NCT05733598
Combination of TATE and PD-1 Inhibitor in Liver Cancer
Teclison
NCT03259867
A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3
Replimune
NCT06887348
Psychoeducational Intervention for Patients With Hepatocellular Carcinoma
Massachusetts General Hospital
NCT06541990
A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC
University of Alabama at Birmingham
NCT06294548
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
Anwaar Saeed
NCT06698250
Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC
H. Lee Moffitt Cancer Center and Research Institute
NCT06553885
HepQuant: Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer
Montefiore Medical Center
NCT06899152
Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant
Icahn School of Medicine at Mount Sinai
NCT07059494
GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies
National Cancer Institute (NCI)
NCT05003895
A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer
M.D. Anderson Cancer Center
NCT05394259
Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma
University of California, Irvine
NCT04472767
Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis
The University of Texas Health Science Center at San Antonio
NCT06526104
Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
University of Miami
NCT06902246
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis
Genentech
NCT06096779
Y-90 Treatment Response Using Transarterial Radioembolization
Thomas Jefferson University
NCT07145801
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 47 |
| Phase 2 | 45 |
| Phase 3 | 17 |
| Phase 4 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Hepatocellular Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Hepatocellular Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Hepatocellular Carcinoma page
146 registered trials, 65 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 65 Hepatocellular Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- AstraZeneca sponsors the most Hepatocellular Carcinoma trials on record, review their full trial history before evaluating a specific study. See AstraZeneca's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hepatocellular Carcinoma condition card totals 146 registered trials; most-linked intervention Bevacizumab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.